MedPath

Intragastric pressure as a determinant of satiation.

Phase 1
Conditions
healthy volunteersno medical condition
drugs will be studies because they are known to influence gastric motility.
Registration Number
EUCTR2010-022055-36-BE
Lead Sponsor
ZLeuven
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Healthy volunteers (18-45 years) who have no bowel symptoms and who are in good general health are eligible for the study.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

• They have relevant underlying disease (cardia, pulmonary, metabolic, kidney or liver disease, …)
• They have a history of esophageal or gastric surgery, or recurrent or intermittent upper gastrointestinal
symptoms (upper abdominal pain, nausea, vomiting, bothersome fullness or early satiation, heartburn,
regurgitation,…)
• They have a history of allergy to several types of drugs or food.
• They have ever been treated for depression
• There is a possibility of becoming pregnant during the study period.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: We set out to investigate whether IGP is a determinant of satiation. To this end we plan to investigate whether:<br>1) sumatriptan reduces IGP during food intake and which effect this has on satiation (protocol 2: sumatriptan study)<br>2) erythromycine increases IGP during food intake and which effect his has on satiation (protocol 3: erythromycin study)<br>;Secondary Objective: none;Primary end point(s): liquid nutrient tolerance to reach maximum satiation
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath